Listar por autor "Tabernilla, Andrés"
Mostrando ítems 1-7 de 7
-
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
Pernas, Berta; Grandal, Marta; Pértega-Díaz, Sonia; Cañizares, Angelina; Castro-Iglesias, Ángeles; Mena, Álvaro; Rodríguez-Osorio, Iria; Tabernilla, Andrés; Pedreira, José D.; Poveda, Eva (Oxford University Press, 2015-12-24)[Abstract] Objectives. The objective of this study was to evaluate the prevalence of blips and risk of virological failure (VF) among HIV-infected patients with sustained virological suppression (HIV-RNA <50 copies/mL) on ... -
Caracterización epidemiológica, clínica y virológica de los nuevos diagnósticos de infección por VHC en Galicia (2014-2015)
Pernas, Berta; Tabernilla, Andrés; Castro-Iglesias, Ángeles; Trigás, M.; Morano, L.; Mariño, A.; Rodríguez-Osorio, Iria; Ocampo, A.; Pereiro, C.; Poveda, Eva (Elsevier, 2016) -
Characterization of chronic HCV infection in Northwest Spain: impact of the treatment strategic plan of the Spanish National Health Service on HCV cure
Grandal, Marta; Pernas, Berta; Mariño, Ana; Álvarez, Hortensia; Tabernilla, Andrés; Castro-Iglesias, Ángeles; Mena, Álvaro; Delgado, Manuel; Pértega-Díaz, Sonia; Poveda, Eva (Wiley, 2017-03-14)[Abstract] The aim of the study was to characterize HCV infection in Northwest Spain and assess the impact of the Spanish Strategic Plan to cure HCV infection. Overall, 387 patients were included (60.9% HIV/HCV coinfected ... -
Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors
Pernas, Berta; Grandal, Marta; Tabernilla, Andrés; Cid-Silva, Purificación; Pértega-Díaz, Sonia; Castro-Iglesias, Ángeles; Mena, Álvaro; Margusino-Framiñán, Luis; Pedreira, José D.; Poveda, Eva (Wiley, 2016-06-06)[Abstract] The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period ... -
Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication
Pernas, Berta; Rego-Pérez, Ignacio; Tabernilla, Andrés; Balboa-Barreiro, Vanesa; Relaño, Sara; Grandal, Marta; Crespo, Manuel; Mena, Álvaro; Castro-Iglesias, Ángeles; Blanco García, Francisco J; Poveda, Eva (Oxford, 2017-08-31)[Abstract] Objectives. To evaluate plasma mitochondrial DNA (mtDNA) levels among HIV-infected patients and its potential role as a biomarker of residual viral replication. Methods. HIV-infected patients on follow-up at a ... -
Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies
Grandal, Marta; Pernas, Berta; Tabernilla, Andrés; Mariño, Ana; Álvarez, Hortensia; Valcarce, Nieves; Mena, Álvaro; Castro-Iglesias, Ángeles; Pérez, Ana B.; Delgado, Manuel; Poveda, Eva (Wiley, 2018-02-10)[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A region is mainly focused on patients with ... -
Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients
Rodríguez-Osorio, Iria; Cid-Silva, Purificación; Morano, Luis; Castro-Iglesias, Ángeles; Suárez, Marta; Delgado, Manuel; Margusino-Framiñán, Luis; Meijide, Héctor; Pernas, Berta; Tabernilla, Andrés; Pedreira, José D.; Mena, Álvaro; Poveda, Eva (Elsevier, 2017-01-18)[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have ...